Recent advances in drug design and drug discovery for androgen- dependent diseases.

This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia.

It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.

Current medicinal chemistry. 2016 Feb 10 [Epub ahead of print]

Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva, Eugene Bratoeff

DEPARTAMENTO DE SISTEMAS BIOLÓGICOS, UNIVERSIDAD AUTÓNOMA METROPOLITANA-XOCHIMILCO CALZADA DEL HUESO No. 1100, MÉXICO, D. F. , C. P. 04960, MÉXICO.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe